Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ABBV
stocks logo

ABBV

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
16.40B
+8.58%
3.353
+55.24%
14.71B
+10.25%
3.051
+24.02%
16.59B
+7.57%
3.637
+22.46%
Estimates Revision
The market is revising Upward the revenue expectations for AbbVie Inc. (ABBV) for FY2025, with the revenue forecasts being adjusted by 0.39% over the past three months. During the same period, the stock price has changed by 7.60%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.39%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-11.12%
In Past 3 Month
Stock Price
Go Up
up Image
+7.60%
In Past 3 Month
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 246.59 USD with a low forecast of 203.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
24 Analyst Rating
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 246.59 USD with a low forecast of 203.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
9 Hold
0 Sell
Moderate Buy
Current: 228.710
sliders
Low
203.00
Averages
246.59
High
289.00
Current: 228.710
sliders
Low
203.00
Averages
246.59
High
289.00
Scotiabank
Outperform
initiated
$280
2025-11-12
Reason
Scotiabank
Price Target
$280
2025-11-12
initiated
Outperform
Reason
Scotiabank initiated coverage of AbbVie with an Outperform rating and $280 price target.
H.C. Wainwright
Patrick Trucchio
Buy
downgrade
$40 -> $35
2025-11-10
Reason
H.C. Wainwright
Patrick Trucchio
Price Target
$40 -> $35
2025-11-10
downgrade
Buy
Reason
H.C. Wainwright analyst Patrick Trucchio lowered the firm's price target on GH Research (GHRS) to $35 from $40 and keeps a Buy rating on the shares. Competitive momentum in short-acting psychedelics, led by advancing programs such as Atai Beckley's (ATAI) BPL-003 and AbbVie's (ABBV) GM-2505, combined with the ongoing FDA hold, led the firm to fine-tune its expected GH001 launch timing and peak share in treatment-resistant depression, resulting in a revised price target. However, it continues to view GH001 as a leading asset within the short-duration psychedelics space and notes that its revised target still represents "robust upside potential."
UBS
Trung Huynh
Neutral
maintain
$195 -> $220
2025-11-07
Reason
UBS
Trung Huynh
Price Target
$195 -> $220
2025-11-07
maintain
Neutral
Reason
UBS analyst Trung Huynh raised the firm's price target on AbbVie to $220 from $195 and keeps a Neutral rating on the shares. The firm updated its model following the Q3 earnings report.
Piper Sandler
David Amsellem
Overweight
maintain
$284 -> $289
2025-11-05
Reason
Piper Sandler
David Amsellem
Price Target
$284 -> $289
2025-11-05
maintain
Overweight
Reason
Piper Sandler analyst David Amsellem raised the firm's price target on AbbVie to $289 from $284 and keeps an Overweight rating on the shares following quarterly results. The firm cites higher Skyrizi estimates in 2026-plus and higher estimates for key products in the Neuroscience segment, which it believes remains a largely under-the-radar business.
DZ Bank
Buy
to
Hold
downgrade
$237
2025-11-04
Reason
DZ Bank
Price Target
$237
2025-11-04
downgrade
Buy
to
Hold
Reason
DZ Bank downgraded AbbVie to Hold from Buy with a $237 price target.
Citi
Geoff Meacham
Neutral
downgrade
$240 -> $235
2025-11-03
Reason
Citi
Geoff Meacham
Price Target
$240 -> $235
2025-11-03
downgrade
Neutral
Reason
Citi analyst Geoff Meacham lowered the firm's price target on AbbVie to $235 from $240 and keeps a Neutral rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for AbbVie Inc (ABBV.N) is 16.78, compared to its 5-year average forward P/E of 12.84. For a more detailed relative valuation and DCF analysis to assess AbbVie Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
12.84
Current PE
16.78
Overvalued PE
15.73
Undervalued PE
9.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
11.96
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
13.97
Undervalued EV/EBITDA
9.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.80
Current PS
0.00
Overvalued PS
5.68
Undervalued PS
3.93
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ABBV News & Events

Events Timeline

(ET)
2025-12-01
16:10:00
Amneal Pharmaceuticals Receives FDA Approval for Cyclosporine Ophthalmic Emulsion 0.05%
select
2025-11-28 (ET)
2025-11-28
07:03:47
AbbVie Secures Favorable CDA-AMC Reimbursement Endorsement for SKYRIZI
select
2025-11-26 (ET)
2025-11-26
07:35:33
CollPlant to Cut Workforce by 25%
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
12-02NASDAQ.COM
Significant Inflows Observed in ETFs - XLV, JNJ, ABBV, MRK

  • 52 Week Range Analysis: XLV's share price has a 52-week low of $127.35 and a high of $158.95, with the last trade recorded at $155.06.

  • Understanding ETFs: Exchange traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.

  • Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (old units destroyed), impacting the underlying holdings.

  • Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.

[object Object]
Preview
3.5
12-02PRnewswire
AbbVie Showcases New Blood Cancer Research Data, Reinforcing Market Leadership
  • Research Advances: AbbVie will unveil new data at the 2025 American Society of Hematology Congress, showcasing research across multiple blood cancers, including multiple myeloma and chronic lymphocytic leukemia, further solidifying its leadership in blood cancer innovation.
  • Clinical Data: The new data will feature multiple oral and poster presentations highlighting investigational compounds like ABBV-383 and PVEK, as well as approved therapies EPKINLY® and VENCLEXTA®, demonstrating efficacy and safety across various hematologic malignancies.
  • Standard of Care Enhancement: AbbVie's VP Daejin Abidoye stated that these presentations emphasize the company's commitment to raising the standard of care in blood cancer, aiming to address the heterogeneity of blood cancers through innovative therapies tailored to diverse patient needs.
  • Pipeline Diversity: AbbVie's portfolio includes T-cell engagers, BCL-2 inhibitors, and antibody-drug conjugates, showcasing the depth and diversity of its pipeline in blood cancer treatment, which is expected to drive future market growth.
[object Object]
Preview
9.0
12-02PRnewswire
AbbVie Reports ECLIPSE Phase 3 Results for Atogepant, Significantly Alleviating Migraine Symptoms
  • Clinical Trial Success: AbbVie's ECLIPSE Phase 3 trial demonstrated that Atogepant significantly outperformed placebo in treating migraines, achieving a pain-free rate of 24.3% compared to 13.1% for placebo two hours post-treatment, which will provide new treatment options for migraine sufferers.
  • Multiple Endpoints Met: Out of 16 key secondary endpoints, 12 showed statistical significance, further validating Atogepant's potential in alleviating migraine symptoms, which could transform existing treatment protocols.
  • Widespread Impact: With migraines affecting approximately 14% of the global population, particularly women aged 25 to 55, the success of Atogepant is expected to alleviate economic burdens on this demographic, likely improving patients' quality of life.
  • Regulatory Submission Progress: AbbVie has submitted a marketing application for Atogepant to the European Medicines Agency, and if approved, it will offer a new acute migraine treatment option, further solidifying AbbVie's market position in the neuroscience sector.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is AbbVie Inc (ABBV) stock price today?

The current price of ABBV is 228.71 USD — it has decreased -0.66 % in the last trading day.

arrow icon

What is AbbVie Inc (ABBV)'s business?

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

arrow icon

What is the price predicton of ABBV Stock?

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 246.59 USD with a low forecast of 203.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is AbbVie Inc (ABBV)'s revenue for the last quarter?

AbbVie Inc revenue for the last quarter amounts to 15.78B USD, increased 9.10 % YoY.

arrow icon

What is AbbVie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

AbbVie Inc. EPS for the last quarter amounts to 0.10 USD, decreased -88.64 % YoY.

arrow icon

What changes have occurred in the market's expectations for AbbVie Inc (ABBV)'s fundamentals?

The market is revising Upward the revenue expectations for AbbVie Inc. (ABBV) for FY2025, with the revenue forecasts being adjusted by 0.39% over the past three months. During the same period, the stock price has changed by 7.60%.
arrow icon

How many employees does AbbVie Inc (ABBV). have?

AbbVie Inc (ABBV) has 55000 emplpoyees as of December 05 2025.

arrow icon

What is AbbVie Inc (ABBV) market cap?

Today ABBV has the market capitalization of 404.22B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free